OTCMKTS:DSNKY Daiichi Sankyo (DSNKY) Stock Price, News & Analysis $24.40 -0.15 (-0.61%) As of 08/8/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestBuy This Stock About Daiichi Sankyo Stock (OTCMKTS:DSNKY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Daiichi Sankyo alerts:Sign Up Key Stats Today's Range$24.14▼$24.4250-Day Range$21.36▼$27.2052-Week Range$20.92▼$42.48Volume198,526 shsAverage Volume223,796 shsMarket Capitalization$46.22 billionP/E Ratio23.69Dividend Yield1.19%Price TargetN/AConsensus RatingStrong Buy Company Overview Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan. Read More Receive DSNKY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daiichi Sankyo and its competitors with MarketBeat's FREE daily newsletter. Email Address DSNKY Stock News HeadlinesDaiichi Sankyo Co. Ltd. ADR (DSNKY) Stock Price Today - WSJJuly 18, 2025 | wsj.comDaiichi Sankyo Co Ltd ADR News (DSNKY) - Investing.comJune 26, 2025 | investing.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal. | Brownstone Research (Ad)FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For Type Of Lung CancerJune 24, 2025 | benzinga.comDaiichi Sankyo, AstraZeneca Announce Promising DATROWAY Combination Data in NSCLCJune 2, 2025 | msn.comMerck, Daiichi Sankyo pull marketing application for lung cancer therapyMay 29, 2025 | msn.comDaiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCOMay 22, 2025 | businesswire.comWayfinder Biosciences and Daiichi Sankyo collaborate to develop novel RNA-targeting therapies for neurodegenerative diseaseApril 15, 2025 | tmcnet.comSee More Headlines DSNKY Stock Analysis - Frequently Asked Questions How have DSNKY shares performed this year? Daiichi Sankyo's stock was trading at $27.29 at the beginning of the year. Since then, DSNKY stock has decreased by 10.6% and is now trading at $24.40. How were Daiichi Sankyo's earnings last quarter? Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY) released its earnings results on Friday, April, 25th. The company reported $0.30 EPS for the quarter. The firm earned $3.40 billion during the quarter. Daiichi Sankyo had a net margin of 15.65% and a trailing twelve-month return on equity of 17.92%. How do I buy shares of Daiichi Sankyo? Shares of DSNKY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings4/25/2025Today8/09/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:DSNKY Previous SymbolOTCMKTS:DSNKY CIKN/A Webwww.daiichisankyo.com Phone(136) 225-1111FaxN/AEmployees17,435Year FoundedN/AProfitability EPS (Trailing Twelve Months)$1.03 Trailing P/E Ratio23.69 Forward P/E Ratio33.42 P/E Growth1.26Net Income$1.95 billion Net Margins15.65% Pretax Margin18.85% Return on Equity17.92% Return on Assets8.61% Debt Debt-to-Equity Ratio0.06 Current Ratio2.53 Quick Ratio1.85 Sales & Book Value Annual Sales$12.39 billion Price / Sales3.73 Cash Flow$1.25 per share Price / Cash Flow19.56 Book Value$5.61 per share Price / Book4.35Miscellaneous Outstanding Shares1,894,350,000Free FloatN/AMarket Cap$46.22 billion OptionableNot Optionable BetaN/A Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (OTCMKTS:DSNKY) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daiichi Sankyo Co., Ltd. - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Daiichi Sankyo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.